NOAC Management in Atrial Fibrillation
Definition
Non-vitamin K antagonist oral anticoagulants (NOACs — also called DOACs) comprise four approved agents for stroke prevention in AF: dabigatran (direct thrombin inhibitor) and apixaban, rivaroxaban, edoxaban (FXa inhibitors). NOACs are preferred over VKAs in newly initiated anticoagulation (ESC Class I/A) except in EHRA Type 1 VHD (mechanical prosthetic valve or moderate-to-severe mitral stenosis). The EHRA Practical Guide 2018 organizes NOAC use in AF around 20 clinical scenarios; several areas have since been updated by AUGUSTUS, ENTRUST-AF PCI, EPIC-CAD, and COBRRA.
Key Concepts
Eligibility — EHRA VHD Classification
- Type 1 (VKA-mandatory): mechanical prosthetic heart valve, moderate-to-severe mitral stenosis (usually rheumatic) — NOACs contraindicated (sources/noac-ehra-2018, rating: high)
- Type 2 (NOAC-eligible): all other native valvular disease, bioprosthetic valves (>3 months post-op, not for rheumatic mitral stenosis), mitral repair, TAVI + AF, HCM + AF (sources/noac-ehra-2018, rating: high)
- HCM + AF: no mechanistic rationale for NOAC inferiority vs VKA; patients may be eligible (sources/noac-ehra-2018, rating: high)
Drug Pharmacokinetics and Renal Clearance
Key differentiators determining drug choice in CKD and drug-drug interaction risk:
| NOAC | Renal clearance (unchanged drug) | CYP3A4 | Protein binding | Half-life |
|---|---|---|---|---|
| Dabigatran | 80% | No | 35% | 12–17h |
| Edoxaban | 50% | Minimal | 55% | 10–14h |
| Rivaroxaban | 35% | Yes (18%) | 95% | 5–13h |
| Apixaban | 27% | Yes (25%) | 87% | 12h |
| (sources/noac-ehra-2018, rating: high) |
CKD Dosing
- Use Cockcroft-Gault (not CKD-EPI) for all NOAC dosing decisions (sources/noac-ehra-2018, rating: high)
- Renal monitoring interval: reassess every CrCl/10 months (e.g., CrCl 30 = every 3 months)
- Dabigatran most CKD-sensitive (80% renal); not approved CrCl <30; prefer FXa inhibitors for CrCl 15–29
- Apixaban: lowest renal dependence (27%); bleeding benefit vs warfarin increases with declining CrCl
- Edoxaban: paradoxically less effective vs warfarin at CrCl >95 mL/min (FDA warning 2015)
- CrCl <15: no NOAC officially indicated
Standard Dosing and Dose Reduction Criteria (AF)
| NOAC | Standard | Dose-reduced | Criteria |
|---|---|---|---|
| Apixaban | 5mg BID | 2.5mg BID | ≥2 of: age ≥80, weight ≤60kg, creatinine ≥133 μmol/L |
| Dabigatran | 150mg BID | 110mg BID | Age >75, high bleed risk, CrCl 30–49 |
| Edoxaban | 60mg OD | 30mg OD | Weight ≤60kg, CrCl ≤50, strong P-gp inhibitor |
| Rivaroxaban | 20mg OD | 15mg OD | CrCl ≤50 |
| (Never use lower doses outside tested reduction algorithms — underdosing → higher stroke rates, no safety benefit) (sources/noac-ehra-2018, rating: high) |
Liver Disease Dosing (Child-Pugh)
- Child A: standard dosing for all NOACs
- Child B: caution for dabigatran/apixaban/edoxaban; avoid rivaroxaban (>2-fold exposure)
- Child C: all NOACs contraindicated (sources/noac-ehra-2018, rating: high)
Drug-Drug Interactions
- P-gp inhibitors (verapamil, dronedarone, amiodarone, quinidine, ticagrelor loading): ↑ all NOAC levels
- Dronedarone + dabigatran: contraindicated (strong P-gp effect)
- Verapamil + dabigatran: use 110mg BID
- CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St. John's wort): markedly ↓ rivaroxaban and apixaban levels; avoid
- Rivaroxaban/apixaban + strong CYP3A4+P-gp inhibitors (ketoconazole, ritonavir): avoid
- Food interaction: rivaroxaban 15/20mg MUST be taken with food (+39% AUC); others: no effect (sources/noac-ehra-2018, rating: high)
Measuring NOAC Effect
- PT/aPTT: unreliable for NOAC quantification
- Dabigatran: dTT or ECA (quantitative); TT (qualitative — normal excludes all dabigatran); aPTT (qualitative only)
- FXa inhibitors: calibrated anti-FXa chromogenic assay (quantitative); do NOT use PT-to-INR conversion
- Expected levels (AF standard doses): dabigatran peak 64–443 ng/mL / trough 31–225; apixaban 69–321/34–230; edoxaban 91–321/31–230; rivaroxaban 184–343/12–137 (sources/noac-ehra-2018, rating: high)
- Routine monitoring not recommended; reserved for emergency, uncertain adherence, extreme weight, complex interactions (sources/noac-ehra-2018, rating: high)
Bleeding Management
Three-tier severity approach:
- Nuisance/minor: delay ≤1 dose; treat cause; local anti-fibrinolytics (tranexamic acid)
- Major non-life-threatening: causal hemostasis; tranexamic acid 1g IV q6h; desmopressin 0.3mg/kg IV; maintain diuresis (dialysis for dabigatran only)
- Life-threatening: specific reversal — idarucizumab 5g IV for dabigatran (RE-VERSE AD); andexanet alfa for FXa inhibitors (approved 2018+); (a)PCC if specific reversal unavailable; FFP is NOT useful (sources/noac-ehra-2018, rating: high)
Cardioversion Anticoagulation
- AF ≥48h (or unknown): ≥3 weeks OAC before cardioversion OR TOE-guided early strategy (single NOAC dose ≥4h before)
- Post-cardioversion: mandatory OAC ≥4 weeks regardless of CHA₂DS₂-VASc
- LAA thrombus on TOE: do NOT cardiovert; treat with NOAC (rivaroxaban resolution rate 41.5% — X-TRA)
- AF <48h: single NOAC dose 2–4h before may substitute for LMWH; TOE-guided if CHA₂DS₂-VASc ≥4
- Long-term OAC post-CV by stroke risk score, not by cardioversion outcome (sources/noac-ehra-2018, rating: high)
Follow-Up and Adherence
- Follow-up: monthly initially; then ≥every 3 months
- Blood sampling: yearly; 6-monthly if ≥75 or frail; every CrCl/10 months if CrCl <60
- HAS-BLED validated in NOAC patients; high bleeding risk does NOT justify OAC withdrawal (stroke and bleed risks track together)
- OD regimens generally better adherence vs BID
- SAMe-TT2R2 score ≥3: predicts poor VKA control; useful if VKA required before NOAC access (sources/noac-ehra-2018, rating: high)
Contradictions / Open Questions
- Head-to-head NOAC comparisons: 2018 guide lacks direct NOAC vs NOAC RCT data for AF stroke prevention (indirect comparisons only); COBRRA 2026 now directly compares apixaban vs rivaroxaban for VTE
- Routine plasma level monitoring: no hard outcome data exist showing level-guided dose adjustment improves outcomes; current guidance is expert opinion
- Post-cardioversion anticoagulation timing in AF <48h: optimal duration uncertain; 48h threshold is not binary (even 12–48h AF carries thromboembolic risk from cardioversion)
- NOAC in TAVI + AF: GALILEO trial (rivaroxaban after TAVI) published post-2018 showing harm; antiplatelet-based strategy may be preferred
- Cancer + AF: LMWH preference (2018 standard) now challenged by DOAC trials (CARAVAGGIO, Hokusai-Cancer); GI bleeding risk remains NOAC concern in GI tumors (sources/noac-ehra-2018, rating: high; sources/Cancer-Associated-VTE)
Connections
- Related to concepts/AF-CARE — NOAC anticoagulation is the "Avoid stroke" pillar
- Related to concepts/NOAC-Perioperative — perioperative interruption rules
- Related to concepts/AF-Stable-CAD-Antithrombotic — dual vs triple antithrombotic post-PCI
- Related to concepts/CHA2DS2-VA — stroke risk score driving anticoagulation decision
- Related to concepts/Subclinical-AF — NOAC in device-detected low-burden AF (ARTESIA, NOAH)
- Related to concepts/Venous-Thromboembolism-Anticoagulation — cross-indication dosing differences
- Related to concepts/Cancer-Associated-VTE — NOAC in malignancy
Sources
- sources/noac-ehra-2018 — primary source (2018 EHRA Practical Guide)